Antibodies specific for ELAM-1 and the use thereof

• US 5,403,713 A
• Filed: 08/05/1993
• Issued: 04/04/1995
• Est. Priority Date: 11/14/1988
• Status: Expired due to Term

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Bevilacqua, Michael P., Gimbrone, Michael A.
• Primary Examiner(s): Nucker, Christine M.
• Assistant Examiner(s): Cunningham, Thomas M.
• Application Number:
  US08/102,510
• Time in Patent Office: 607 Days
• Field of Search: 530/391.3, 530/388.22, 436/501, 436/512, 436/504, 424/858
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/70564 Selectins, e.g. CD62
• CPC Class Codes: C07K 16/2854 against selectins, e.g. CD62

Abstract

The invention relates to a method for detecting ELAM-1 expression in a patient comprising (i) administration of a detectable amount of a labelled ELAM-1 specific antibody (or an anti-ELAM 1 antibody fragment) and a pharmaceutically acceptable carrier, and (ii) detecting the label. ELAM-1 is an endothelial cell surface glycoprotein which participates in endothelialleukocyte adhesion. Induction of ELAM-1 expression has been detected on endothelial cells at sites of inflammation.

Claims

1. A method for detecting ELAM-1 expression in a patient, comprising (i) administering to said patient for a time, and under conditions sufficient for binding, a pharmaceutical composition comprising a detectable amount of a labelled anti-ELAM-1 H18/7 monoclonal antibody, or a labelled antibody fragment comprising an Fab domain thereof, and a pharmaceutically acceptable carrier, and (ii) detecting said label.